Business
Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference
SALT LAKE CITY, March 3, 2021- /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine
About this update from Lipocine Inc.
[{"type":"text","content":"SALT LAKE CITY, March 3, 2021- /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical data for lead candidate TLANDO™ will be presented at the ENDO 2021 Conference, to take place March 20-23, 2021. TLANDO is an oral testosterone replacement therapy (\"TRT\") product candidate being developed for adult males with conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.\n\n \n \n \n \n \n \n\n \nTitle: Low Testosterone in Males may Warrant Liver Health Assessment InterventionSession Type: Poster SessionSession: P12 - Cardiovascular EndocrinologyDate: March 20, 2021 11:00 a.m. E.T., On-DemandLink: https://www.abstractsonline.com/pp8/#!/9188/presentation/3323Title: Efficacy and Safety of TLANDO, a Novel Oral Easy to Prescribe and Use TRT OptionSession Type: Poster SessionSession: P25 – Endocrine Disrupting Compounds: Mechanisms of Action and Clinical ImplicationsDate: March 20, 2021 11:00 a.m. E.T., On-DemandLink: https://www.abstractsonline.com/pp8/#!/9188/presentation/1912Title: TLANDO, a Novel Oral TRT, Improves Sexual and Mental Domain Outcomes in Hypogonadal MenSession Type: Poster SessionSession: P25 – Endocrine Disrupting Compounds: Mechanisms of Action and Clinical ImplicationsDate: March 20, 2021 11:00 a.m. E.T., On-DemandLink: https://www.abstractsonline.com/pp8/#!/9188/presentation/1915About LipocineLipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testo...